Glucocorticoid Prescribing Trends in Congenital Adrenal Hyperplasia, 2017 to 2023 - PubMed
3 days ago
- #Congenital Adrenal Hyperplasia
- #Prescribing Trends
- #Glucocorticoid
- Study examines glucocorticoid prescribing trends for congenital adrenal hyperplasia (2017-2023).
- Only 5% of patients transitioned to modern glucocorticoids (Acecort®, Alkindi®, Efmody®, Plenadren®).
- Highest adoption seen in high-income Western European countries.
- Alkindi® prescribed exclusively to patients under 8 years; 97% of Efmody® users were 7+ years.
- By 2023, availability varied: Alkindi® (54%), Efmody® (46%), Plenadren® (33%), Acecort® (15%).
- Key barriers: legislative approval, supply chain issues, and high costs.